NCT04595162: A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL |
|
|
| Not yet recruiting | 1 | 12 | NA | GC019F | Peking University Third Hospital, Gracell Biotechnology Ltd. | B-cell Acute Lymphoblastic Leukemia | 12/23 | 12/35 | | |
ChiCTR2100054321: Phase I/II clinical trial of GC019F injection in the treatment of CD19 positive relapsed or refractory acute B lymphocytic leukemia |
|
|
| Not yet recruiting | 1 | 6 | | 1.5x10^4CAR+T cells/kg ;3.0x10^4CAR+T cells/kg | Peking University Third Hospital; Gracell Biotechnology (Shanghai) Co., LTD., Gracell Biotechnology (Shanghai) Co., LTD. | CD19-positive relapsed or refractory acute B lymphocytic leukemia | | | | |
